

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 4 of 4 returned.**☐ 1. Document ID: US 20030049286 A1

L4: Entry 1 of 4

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049286

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030049286 A1

TITLE: Stable skin care compositions containing a retinoid and a retinoid booster system

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Granger, Stewart Paton	Paramus	NJ	US	
Chandar, Prem	Closter	NJ	US	
Scott, Ian Richard	Allendale	NJ	US	

US-CL-CURRENT: 424/401; 514/559, 514/725, 514/763

ABSTRACT:

A stable skin care composition containing about 0.0001% to about 50% of at least one retinoid booster, about 0.001% to about 10% of a retinoid; and a cosmetically acceptable vehicle, wherein the stable skin care composition is contained in a package so that the composition is out of contact with oxygen.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC
Draw Desc	Image										

☐ 2. Document ID: US 20020168389 A1

L4: Entry 2 of 4

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168389

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020168389 A1

TITLE: Stable skin conditioning compositions containing retinoid boosters

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chandar, Prem	Closter	NJ	US	
Zhou, Yan	Montville	NJ	US	
Granger, Stewart Paton	Paramus	NJ	US	
Scott, Ian Richard	Allendale	NJ	US	

US-CL-CURRENT: 424/401; 514/725

ABSTRACT:

A stable oil-in-water emulsion comprising a retinoid, at least one booster compound, and a cosmetically acceptable vehicle, wherein the oil phase of the oil-in-water emulsion has a peroxide value of less than or equal to 12.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw Desc	Image										

☐ 3. Document ID: US 20020142016 A1

L4: Entry 3 of 4

File: PGPB

Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020142016

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020142016 A1

TITLE: Stable skin care product containing a retinoid and a retinoid booster system in a dual compartment package

PUBLICATION-DATE: October 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Granger, Stewart Paton	Paramus	NJ	US	
Chandar, Prem	Closter	NJ	US	
Scott, Ian Richard	Allendale	NJ	US	

US-CL-CURRENT: 424/401; 514/725

ABSTRACT:

A stable skin care product comprising a first composition comprising about 0.001% to about 10% of a retinoid; a second composition comprising about 0.0001% to about 50% of at least one retinoid booster; a first compartment for storing the first composition, wherein the first compartment keeps the first composition out of contact with oxygen; and a second compartment for storing the second composition, the first and second compartments being joined together.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw Desc	Image										

☐ 4. Document ID: US 5856189 A

L4: Entry 4 of 4

File: USPT

Jan 5, 1999.

US-PAT-NO: 5856189

DOCUMENT-IDENTIFIER: US 5856189 A

TITLE: Cell culture model for drug bioavailability

DATE-ISSUED: January 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Watkins; Paul B.	Ann Arbor	MI		
Schmiedlin-Ren; Phyllissa	Brighton	MI		

US-CL-CURRENT: 435/375; 435/352, 435/363, 435/366, 435/370, 435/384

ABSTRACT:

A model utilizing cells for assessing oral bioavailability and potential drug-drug interactions of pharmacological agents is described. The model subjects cells (e.g., Caco-2 cells) to conditions that result in reliable expression of catalytically-active CYP3A4 at levels that appear to be comparable to levels present in mature enterocytes. These conditions include plating of selected clones on an extracellular matrix, exposure to 1.alpha.,25-(OH).sub.2 -D.sub.3 for a defined period of time, and the presence of serum in the medium. The model is useful for defining the role of CYP3A4 in limiting the oral bioavailability of many pharmacological agents and in drug-drug interactions involving CYP3A4 substrates that are believed to occur largely at the level of the intestine.

27 Claims, 17 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 17

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw. Desc	Image								

KUMC

[Generate Collection](#)[Print](#)

Term	Documents
GLUCURONIDE	2145
GLUCURONIDES	412
(2 AND GLUCURONIDE).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	4
(L2 AND GLUCURONIDE).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	4

Display Format:

-

[Change Format](#)[Previous Page](#)[Next Page](#)